Your browser doesn't support javascript.
loading
Real-World Outcomes of Systemic Therapy in Japanese Patients with Cancer (Tokushukai REAl-World Data Project: TREAD): Study Protocol for a Nationwide Cohort Study.
Shimoyama, Rai; Imamura, Yoshinori; Uryu, Kiyoaki; Mase, Takahiro; Fujimura, Yoshiaki; Hayashi, Maki; Ohtaki, Megu; Ohtani, Keiko; Shinozaki, Nobuaki; Minami, Hironobu.
Afiliação
  • Shimoyama R; Department of General Surgery, Shonankamakura General Hospital, Kamakura 247-8533, Japan.
  • Imamura Y; Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
  • Uryu K; Department of Medical Oncology, Yao Tokushukai General Hospital, Yao 581-0011, Japan.
  • Mase T; Department of Breast Surgery, Ogaki Tokushukai Hospital, Ogaki 503-0015, Japan.
  • Fujimura Y; Tokushukai Information System Inc., Osaka 530-0001, Japan.
  • Hayashi M; Mirai Iryo Research Center Inc., Tokyo 102-0083, Japan.
  • Ohtaki M; deCult Co., Ltd., Hatsukaichi 739-0413, Japan.
  • Ohtani K; deCult Co., Ltd., Hatsukaichi 739-0413, Japan.
  • Shinozaki N; Department of General Surgery, Shonankamakura General Hospital, Kamakura 247-8533, Japan.
  • Minami H; General Incorporated Association Tokushukai, Tokyo 102-0074, Japan.
Healthcare (Basel) ; 10(11)2022 Oct 28.
Article em En | MEDLINE | ID: mdl-36360487
Cohort studies using large-scale databases have become increasingly important in recent years. The Tokushukai Medical Group is a leading medical group in Japan that includes 71 general hospitals nationwide from Hokkaido to Okinawa, with a total of 18,000 beds, and a unified electronic medical record system. This retrospective cohort study aims to evaluate the real-world outcomes of systemic therapy for Japanese patients with cancer using this merit of scale. All adult patients with cancer who received systemic therapy using a centrally registered chemotherapy protocol system at 46 hospitals from April 2010 to March 2020 will be identified (~48,850 patients). Key exclusion criteria include active double cancer and inadequate data extraction. Data will be obtained through electronic medical records, diagnosis procedure combination data, medical prescription data, and the national cancer registration system that includes sociodemographic variables, diagnostic and laboratory tests, concomitant drug prescriptions, cost, and overall survival. Kaplan-Meier estimates will be calculated for time-to-event analyses. Stratified/conventional Cox proportional hazards regression analyses will be conducted to examine the relationships between overall survival and related factors. Our findings provide important insights for future research directions, policy initiatives, medical guidelines, and clinical decision-making.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article